FIELD: cellular biology; medicine.
SUBSTANCE: present invention relates to the field of cellular biology and medicine, in particular to a method for in vitro targeting a stem cell expressing phosphatidylserine, as well as a molecule containing a useful load for use in this method. For implementation of the method, cells are brought into contact with the molecule containing the useful load related to a gamma-carboxyglutamic acid component (hereinafter – GLA-component). The specified GLA-component contains GLA domain or its active fragment with a conservative motive Gla-x(3)-Gla-x-Cys, modified with vitamin K-dependent post-translation carboxylation of glutamate residues in an amino acid sequence. The specified fragment is less than the whole domain and saves at least 50% of activity of a native full-sized domain in in vitro analysis, and activity of GLA domain is a capability of binding phosphatidylserine, and the specified molecule does not contain an active catalytic domain detected in full-sized protein below EGF domain from GLA protein.
EFFECT: present invention allows for specific targeting stem cells expressing phosphatidylserine, which can be useful in diagnostics or isolation of stem cells for further manipulation to make them useful in therapeutic use.
34 cl, 30 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TARGETED IMPACT ON EXOSOMES | 2018 |
|
RU2781640C2 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| HUMANIZED ANTIBODIES AGAINST BASIGIN AND THEIR APPLICATION | 2017 |
|
RU2755150C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| COMPOSITION FOR TREATING CANCER, COMBINING ANTI-CD26 ANTIBODY AND OTHER ANTI-CANCER AGENT | 2016 |
|
RU2742953C2 |
| PEPTIDES AND PEPTIDOMIMETICS FOR COMBINED USE AND TREATMENT IN A SUBPOPULATION OF PATIENTS WITH CANCER DISEASES | 2014 |
|
RU2732440C2 |
| GLA DOMAINS AS THERAPEUTIC AGENTS | 2014 |
|
RU2705786C2 |
